Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | MGMT | P16455 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957224 | 1.00 | MEN1 (0.41) | MEN1KMT2ACRBNRECQLTTR | |
| SCHEMBL13695963 | 0.88 | CASP2 (0.41) | MEN1KMT2ACRBNTTRCA12 | |
| SCHEMBL30377114 | 0.88 | CASP2 (0.41) | MEN1KMT2ACRBNTTRCA12 | |
| SCHEMBL17282361 | 0.87 | CRBN (0.41) | MEN1KMT2ACRBNTTRSMN1; SMN2 | |
| SCHEMBL18886281 | 0.87 | CRBN (0.41) | MEN1KMT2ACRBNTTRSMN1; SMN2 | |
| SCHEMBL19164024 | 0.86 | CRBN (0.38) | MEN1KMT2ACRBNTTRSMN1; SMN2 | |
| SCHEMBL24795789 | 0.85 | CRBN (0.38) | MEN1KMT2ACRBNTTRSMN1; SMN2 | |
| SCHEMBL18886307 | 0.85 | CRBN (0.38) | MEN1KMT2ACRBNTTRSMN1; SMN2 | |
| SCHEMBL14922170 | 0.85 | CRBN (0.38) | MEN1KMT2ACRBNTTRSMN1; SMN2 | |
| SCHEMBL23234313 | 0.85 | CRBN (0.38) | MEN1KMT2ACRBNTTRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946391-B2 | Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-03 | — | — | US | disclosed |
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | LIG3, LIG1, IGSF11 | MEN1 2942/4885KMT2A 2978/4885CRBN 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.